Overview

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

This was a prospective, open-label, Phase III, multicenter, single-arm trial designed to assess the safety, pharmacokinetics, and pharmacodynamics of an alternative dosing rate of rituximab in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) and follicular non-Hodgkin lymphoma (NHL).

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Analgesics
Antipyretics
Cyclophosphamide
Doxorubicin
Histamine Antagonists
Histamine H1 Antagonists
Liposomal doxorubicin
Prednisone
Rituximab
Vincristine